Bioxcel Therapeutics Logo
Previous slide
Next slide

Latest News

VIEW ALL NEWS
Sep 18, 2025
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities RequirementsVIEW RELEASE
Sep 10, 2025
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Sep 04, 2025
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceVIEW RELEASE
VIEW ALL NEWS

Stock Information

BioXcel Therapeutics, Inc.

Sep 18, 2025 01:29 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

3

CHANGE

0.11 (3.62%)
EVENTS
SIGN UP FOR EMAIL ALERTS
Bioxcel Therapeutics Logo
Linkedin-in Twitter

IGALMI is a registered trademark of BioXcel Therapeutics, Inc. 
All other trademarks are the properties of their respective owners.
Copyright © 2025 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

IGALMI is a registered trademark of BioXcel Therapeutics, Inc.
All other trademarks are the properties of their respective owners.
Copyright © 2025 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.